Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(03): 368-379
DOI: 10.4103/ijmpo.ijmpo_201_17
Review Article

Current Treatment Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer: An Indian Perspective

Gupta Sudeep
Department of Medical Oncology, Tata Memorial Centre, ACTREC, Navi Mumbai, Maharashtra, India
,
Chatterjee Sanjoy
Department of Radiation Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Nigade Jagdish
Medical, Roche Products (India) Pvt. Ltd., Mumbai, Maharashtra, India
,
Aggarwal Shyam
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
,
Singhal Manish
Department of Medical Oncology, Indraprastha Apollo Hospitals, New Delhi, India
,
SS Alurkar
Department of Oncology, Apollo Hospitals, Ahmedabad, Gujarat, India
,
Kukreja Anil
Medical, Roche Products (India) Pvt. Ltd., Mumbai, Maharashtra, India
,
BK Smruti
Department of Medical Oncology, Bombay Hospital, Mumbai, Maharashtra, India
,
Nag Shona
Department of Oncology, Jehangir Hospital, Pune, Maharashtra, India
,
Agarwal Amit
Department of Medical Oncology, BL Kapoor Hospital, Delhi, India
,
Agarwal Vijay
Department of Medical Oncology, Healthcare Global, Bengaluru, Karnataka, India
,
R Chacko
Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India
,
Desai Chirag
Hemato-Oncology Clinic, Vedanta Super Speciality Hospital, Ahmedabad, India
,
Goswami Chanchal
Department of Oncology, Medica Superspecialty Hospital, Kolkata, West Bengal, India
,
Keechilat Pavithran
Department of Medical Oncology, Amrita Institute of Medical Sciences, Kochi, Kerala, India
,
Patil Poonam
Department of Medical Oncology, Manipal Hospital, Bengaluru, Karnataka, India
,
Prasad Krishna
Department of Medical Oncology, Kasturba Medical College, Mangalore, Karnataka, India
,
Rajendranath Rejiv
Department of Medical Oncology, Apollo Speciality Hospital, Chennai, Tamil Nadu, India
,
RR Rao
Department of Medical Oncology, Max Super Speciality Hospital, Delhi, India
,
TP Sahoo
Department of Medicine, Chirayu Medical College, Bhopal, Madhya Pradesh, India
,
Singh Ashish
Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India
,
Singh Randeep
Department of Oncology, Artemis Hospital, Gurgaon, Haryana, India
,
Srinivasan Sankar
Department of Medical Oncology, Apollo Speciality Hospital, Chennai, Tamil Nadu, India
,
Warrier Arun
Department of Medical Oncology, Aster Medicity Hospital, Kochi, Kerala, India
,
Swarup Binay
Medical Roche Products (India), Mumbai, Maharashtra, India
,
Bhattacharya Priyanka
Medical Roche Products (India), Mumbai, Maharashtra, India
,
SH Advani
Medical Oncology, Mumbai, Maharashtra, India
› Author Affiliations Financial support and sponsorship Roche Products (India) Pvt. Ltd. provided financial support for this scientific/educational project at no detriment to the freedom to prescribe and to choose treatment. Roche does not recommend or endorse any use, preparation. or administration of the products, which is outside of their prescribing information.
› Further Information
   Permissions and Reprints

Abstract

Human epidermal growth factor receptor 2 (HER2)-positive is an aggressive subtype of breast cancer and has historically been associated with poor outcomes. The availability of various anti-HER2 therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (TDM-1), has remarkably improved the clinical outcomes in patients with HER2-positive metastatic breast cancer (mBC). However, there is a need to optimize treatment within this population, given the wide variability in clinical presentation. Additionally, geographical and socio-economic considerations too need to be taken into account. To clarify and collate evidence pertaining to HER2-positive metastatic breast cancer, a panel of medical and clinical oncologists from across India developed representative clinical scenarios commonly encountered in clinical practice in the country. This was followed by two meetings wherein each clinical scenario was discussed in detail and relevant evidence appraised. The result of this process is presented in this manuscript as evidence followed by therapeutic recommendations of this panel for management of HER2-positive mBC in the Indian population.

Keywords

Human epidermal growth factor receptor 2 positive - India - metastatic breast cancer - targeted therapy


Publication History

Article published online:
17 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-9
    CrossrefPubMedGoogle Scholar
  • 2 Saini KS, Azim HAJr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E. et al. Beyond trastuzumab: New treatment options for HER2-positive breast cancer. Breast 2011; 20 Suppl 3: S20-7
    CrossrefPubMedGoogle Scholar
  • 3 Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P. et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011; 48: 391-6
    CrossrefPubMedGoogle Scholar
  • 4 Doval DC, Sharma A, Sinha R, Kumar K, Dewan AK, Chaturvedi H. et al. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev 2015; 16: 4959-64
    CrossrefPubMedGoogle Scholar
  • 5 Chatterjee S, Saha A, Arun I, Nayak SS, Sinha S, Agrawal S. et al. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: Do pre-NACT ER/PR status act as better prognosticators?. Breast Cancer (Dove Med Press) 2015; 7: 381-8
    Google Scholar
  • 6 Agrawal S, Banswal L, Saha A, Arun I, Datta SS, Chatterjee S. et al. Progesterone receptors, pathological complete response and early outcome for locally advanced breast cancer – A single centre study (PPLB - 01). Indian J Surg Oncol 2016; 7: 397-406
    CrossrefPubMedGoogle Scholar
  • 7 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82
    CrossrefPubMedGoogle Scholar
  • 8 Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
    CrossrefPubMedGoogle Scholar
  • 9 Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43
    CrossrefPubMedGoogle Scholar
  • 10 Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH. et al Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19
    CrossrefPubMedGoogle Scholar
  • 11 Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91
    CrossrefPubMedGoogle Scholar
  • 12 Genentech (A Member of the Roche group); Herceptin® (Trastuzumab) Development Timeline. Available from: https://www.gene.com/media/product-information/herceptin-development-timeline. [Last accessed on 2017 Jun 19].
  • 13 Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A. et al Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA. 31. J Clin Oncol 2015; 33: 1574-83
    CrossrefPubMedGoogle Scholar
  • 14 Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-34
    CrossrefPubMedGoogle Scholar
  • 15 Ciruelos Gil EM, Brufsky A, Im YH, Kim SB, Sinha S, Knott A. et al Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab. J Clin Oncol 2013; 31 15 Suppl: 600
    CrossrefGoogle Scholar
  • 16 Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP. et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): A phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 2015; 16: 816-29
    CrossrefPubMedGoogle Scholar
  • 17 Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study. J Clin Oncol 2017; 35: 141-8
    CrossrefPubMedGoogle Scholar
  • 18 Kadycla. Summary of Product Characteristics. Available from: https://www.ec.europa.eu/health/documents/community-register/2013/20131115127009/anx_127009_en.pdf. [Last accessed on 2017 Jun 19].
  • 19 Swain SM, Clark E, Baselga J. Treatment of HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 1964-5
    CrossrefPubMedGoogle Scholar
  • 20 Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-16
    CrossrefPubMedGoogle Scholar
  • 21 Baselga J, Cortes J, Im SA, Pivot XB, Clark E, Knott A. et al. Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. J Clin Oncol 2012; 30: 597
    CrossrefGoogle Scholar
  • 22 Miles D, Puglisi F, Schneeweiss A, Ciruelos E, Peretz-Yablonski T, Moreno K. et al. 1816 preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Eur J Cancer 2015; 51: S
    CrossrefGoogle Scholar
  • 23 Robert NJ, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D. et al. HER2-positive metastatic breast cancer patients receiving pertuzumab in a community oncology practice setting: Treatment patterns and outcomes. Drugs Real World Outcomes 2017; 4: 1-7
    CrossrefPubMedGoogle Scholar
  • 24 Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M. et al Targeting the PI3K/AKT/mTOR and raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 2013; 39: 935-46
    CrossrefPubMedGoogle Scholar
  • 25 Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M. et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2014; 145: 725-34
    CrossrefPubMedGoogle Scholar
  • 26 Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu YS. et al. Management of HER2-positive breast cancer in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1077-85
    CrossrefPubMedGoogle Scholar
  • 27 Durkee BY, Qian Y, Pollom EL, King MT, Dudley SA, Shaffer JL. et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2016; 34: 902-9
    CrossrefPubMedGoogle Scholar
  • 28 Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-43
    CrossrefPubMedGoogle Scholar
  • 29 Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial. Oncologist 2010; 15: 924-34
    CrossrefPubMedGoogle Scholar
  • 30 André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G. et al Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 580-91
    CrossrefPubMedGoogle Scholar
  • 31 Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA. et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-breast 1): An open-label, randomised, phase 3 trial. Lancet Oncol 2016; 17: 357-66
    CrossrefPubMedGoogle Scholar
  • 32 Urruticoechea A, Rizwanullah M, Im S, Sánchez-Ruiz AC, Lang I, Tomasello G. et al. PHEREXA: A phase III study of trastuzumab + capecitabine +/- pertuzumab for patients who progressed during/after one line of trastuzumab-based therapy in the HER2-positive metastatic breast cancer setting. J Clin Oncol 34 (Suppl. 15) 20.05.2016; Abstract 504
    CrossrefGoogle Scholar
  • 33 Urruticoechea A, Rizwanullah M, Im SA, Ruiz ACS, Láng I, Tomasello G. et al Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol 2017; 35: 3030-8
    CrossrefPubMedGoogle Scholar
  • 34 Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM. et al. Clinical outcome of central nervous system metastases from breast cancer: Differences in survival depending on systemic treatment. J Neurooncol 2012; 106: 303-13
    CrossrefPubMedGoogle Scholar
  • 35 Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH. et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009; 100: 894-900
    CrossrefPubMedGoogle Scholar
  • 36 Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18: 23-8
    CrossrefPubMedGoogle Scholar
  • 37 Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R. et al CEREBEL (EGF111438): A Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2015; 33: 1564-73
    CrossrefPubMedGoogle Scholar
  • 38 Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF. et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: Results from the randomized phase III study CLEOPATRA. Ann Oncol 2014; 25: 1116-21
    CrossrefPubMedGoogle Scholar
  • 39 Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F. et al Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 2013; 14: 64-71
    CrossrefPubMedGoogle Scholar
  • 40 Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M. et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA. Ann Oncol 2015; 26: 113-9
    CrossrefPubMedGoogle Scholar
  • 41 Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz Z. et al Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-breast 3): A randomised, open-label, multicentre, phase 2 trial. Lancet Oncol 2015; 16: 1700-10
    CrossrefPubMedGoogle Scholar
  • 42 Montemurro F, Ellis P, Delaloge S, Wuerstlein R, Anton A, Button P. et al. Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study. Cancer Res 2017; 77 4 Suppl: P1-12-10
    CrossrefGoogle Scholar
  • 43 Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M. et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689-99
    CrossrefPubMedGoogle Scholar
  • 44 Wildiers H, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Yu R. et al. Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study. Cancer Res 2016; 76 (4 Suppl): S5-05
    CrossrefGoogle Scholar
  • 45 Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with erbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-30
    CrossrefPubMedGoogle Scholar
  • 46 Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G. et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study. J Clin Oncol 2012; 30: 2585-92
    CrossrefPubMedGoogle Scholar